Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Arvinas Holding Company (ARVN – Research Report), retaining the price target of $81.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andrew Fein has given his Buy rating due to a combination of factors that highlight the promising potential of Arvinas Holding Company’s ARV-102 program. The first-in-human data presented at the AD/PD 2025 Conference demonstrated that ARV-102 is safe and exhibits robust target engagement of the LRRK2 pathway, which is significant for treating idiopathic Parkinson’s disease. The pharmacokinetics data supports the feasibility of once-daily dosing, and the drug’s ability to penetrate the central nervous system further underscores its therapeutic promise.
Moreover, the data indicated a substantial reduction in LRRK2 levels and other biomarkers, suggesting effective target engagement and potential therapeutic activity. The absence of serious adverse events in the study adds to the drug’s safety profile, making it a compelling candidate for further trials. Given the strong genetic link and the potential applicability to a broad patient population, Fein anticipates that upcoming data from Parkinson’s disease patients will provide further insights into the drug’s safety and efficacy, reinforcing the Buy recommendation.
In another report released today, Guggenheim also maintained a Buy rating on the stock with a $32.00 price target.
Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ARVN in relation to earlier this year.